1ST Bio

1st Biotherapeutics is a clinical-stage biotechnology company focused on developing breakthrough therapies for neurodegenerative diseases, immuno-oncology, and orphan diseases. The company leverages its expertise in small molecule drug discovery to target key pathways involved in disease progression, such as the c-Abl kinase for Parkinson's disease. Its lead candidate, FB-101, is a brain-penetrant c-Abl inhibitor designed to modify the course of neurodegeneration by preventing the accumulation of toxic alpha-synuclein. Beyond neurology, the company is advancing a pipeline of immuno-oncology agents aimed at overcoming resistance to current therapies. 1st Biotherapeutics maintains operations in both South Korea and the United States to facilitate global development and clinical trials. The company's approach combines deep biological insights with efficient medicinal chemistry to address significant unmet medical needs.